NFKB1 and prostate carcinoma: Another study conducted by the same group, using human prostate cancer cell lines, demonstrated the role of apigenin cells’ treatment (2.5 to 20 μM up to 16 h) in the suppression of NF-κB signaling through direct binding and consequent inhibition of IKKa [49].